Polyrizon Ltd. — Form F-1

Polyrizon Ltd., a $21.4M-asset Israeli biotech company, completed two equity financings in 2026: (1) April 2026 RDO of 87,777 ordinary shares at $9.00/share plus 190,000 pre-funded warrants, plus concurrent PIPE of 111,111 pre-funded warrants and 388,888 ordinary share warrants (9.00 exercise price), raising ~$3.1M net; (2) September 2026 RDO of 232,500 ordinary shares at $12.00/share plus 30,000 pre-funded warrants, plus concurrent PIPE of 70,833 pre-funded warrants and 333,333 ordinary share warrants (12.00 exercise price), raising ~$3.5M net. Gross proceeds totaled ~$7.5M. Selling shareholder Armistice Capital holds 943,381 shares (39.3% post-exercise) and may resell up to 404,166 shares via this F-1 registration. Company retains potential ~$4.0M from warrant exercises.